Menu
Fechar
hrs4r
Quiero donar
Firma
NÚRIA SALA-GONZÁLEZ
Posición
Investigador/a Pre-doctoral – R1
Investigadores/as Pre-doctorales – R1
Publicacions

Publicacions

0

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration- resistant prostate cancer: a randomised, double-blind, phase 2 trial

LANCET ONCOLOGY, 2022, 23, 1297-1307 dx.doi.org/10.1016/S1470-2045(22)00498-3
0

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13225830
0

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate

Cancer Management and Research, 2020, 12, 10251-10260 dx.doi.org/10.2147/CMAR.S270392
0

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer

Frontiers in oncology, 2020, 10, 594023-594023 dx.doi.org/10.3389/fonc.2020.594023
0

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Bmc Cancer, 2019, 19, 766-766 dx.doi.org/10.1186/s12885-019-5974-9
0

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

LANCET ONCOLOGY, 2018, 19, 975-986 dx.doi.org/10.1016/S1470-2045(18)30365-6
0

Prognostic and Predictive Factors for Renal Cell Carcinoma

TARGETED ONCOLOGY, 2018, 13, 309-331 dx.doi.org/10.1007/s11523-018-0557-2

Formulari de contacte

Conoce el IDIBGI!

 menu